Erratum: Etranacogene dezaparvovec (AMT-061 phase 2b): Normal/near normal FIX activity and bleed cessation in hemophilia B (Blood Advances (2019) 3:21 (3241-3247) DOI: 10.1182/bloodadvances.2019000811)

A. Von Drygalski, A. Giermasz, G. Castaman

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Erratum: Etranacogene dezaparvovec (AMT-061 phase 2b): Normal/near normal FIX activity and bleed cessation in hemophilia B (Blood Advances (2019) 3:21 (3241-3247) DOI: 10.1182/bloodadvances.2019000811)'. Together they form a unique fingerprint.

Medicine & Life Sciences